The BrIDGs program currently is seeking new collaborations. New proposals are due by September 30, 2017, for inclusion in the next evaluation period. Learn more below about how to request a collaboration.
Prospective collaborators are encouraged to connect with NCATS for timely notification when program updates are announced.
General Proposal Process
Submitted research proposals will be assessed for scientific merit, technical feasibility, fit with available resources and program balance. Steps include:
- Pre-proposal screening with BrIDGs staff to confirm eligibility as a collaborating organization and adequacy of the current data package. This process consists of submission of an abstract for the proposed project and a telephone discussion.
- Submission of a full proposal package through proposalCENTRAL, which includes a formal request (five-page maximum written document) and specified supporting documents. View the detailed instructions (PDF - 188KB) and sample proposal form (PDF - 140KB).
- Internal, confidential programmatic and scientific assessments of the submitted proposal by BrIDGs staff. External drug development experts and an advisory group representing other NIH Institutes and Centers with disease expertise in each proposal area conducts additional evaluations, which are based on four key criteria:
- Strength of current data package
- Target and therapeutic validation
- Feasibility to reach first-in-human status
- Medical impact relative to current standard of care
- In-depth due diligence, including face-to-face meetings with potential collaborators, under the protection of a confidential disclosure agreement on selected projects, leading to a final decision.